Research.Patient.info
Recurrent Ovarian Cancer research hub
3 indexed studies · 2 currently recruiting
- recruitingPHASE1, PHASE2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
This study is testing a new drug, ubamatamab, alone or with cemiplimab, for recurrent ovarian or endometrial cancer. It aims to see how safe it is, how it works in the body, and if it can help treat these cancers.
United States · Australia · Belgium - active not recruitingPHASE1
Phase I Trial of Defactinib and VS-6766.
This study is testing two new drugs, Defactinib and VS-6766, for patients with advanced cancers like certain lung, ovarian, womb, and pancreatic cancers. It aims to find the safest dose and see how well the combination works.
United Kingdom - recruitingPHASE3
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
This study looks at a new drug combination, avutometinib and defactinib, for low-grade serous ovarian cancer that has come back. It compares this new treatment to standard options to see which works best and is safest for patients.
United States · Australia · Belgium